These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11299022)

  • 1. Intravenous immunoglobulin: regulatory perspectives on use and supply.
    Farrugia A; Poulis P
    Transfus Med; 2001 Apr; 11(2):63-74. PubMed ID: 11299022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance.
    Radosevich M; Burnouf T
    Vox Sang; 2010 Jan; 98(1):12-28. PubMed ID: 19660029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
    Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
    Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations.
    Ratko TA; Burnett DA; Foulke GE; Matuszewski KA; Sacher RA
    JAMA; 1995 Jun; 273(23):1865-70. PubMed ID: 7776504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders.
    Emmi L; Chiarini F
    Neurol Sci; 2002 Apr; 23 Suppl 1():S1-8. PubMed ID: 12032582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
    Buchacher A; Iberer G
    Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should therapeutic immunoglobulin be considered a generic product? An evidence-based approach.
    Misbah SA
    J Allergy Clin Immunol Pract; 2013; 1(6):567-72. PubMed ID: 24565702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirements for safety and quality of intravenous immunoglobulin G preparations.
    Rütter GH
    J Neurol Neurosurg Psychiatry; 1994 Nov; 57 Suppl(Suppl):2-5. PubMed ID: 7964845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with the viral safety of immunoglobulins.
    Hellstern P
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S31-4; discussion S35. PubMed ID: 7749046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin: striving for appropriate use.
    Kumar A; Teuber SS; Gershwin ME
    Int Arch Allergy Immunol; 2006; 140(3):185-98. PubMed ID: 16682800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic intravenous immunoglobulins.
    Lemieux R; Bazin R; Néron S
    Mol Immunol; 2005 May; 42(7):839-48. PubMed ID: 15829272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Plasma fractionation in the world: current status].
    Burnouf T
    Transfus Clin Biol; 2007 May; 14(1):41-50. PubMed ID: 17499539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chinese plasma-derived products supply under the lot release management system in 2007-2011.
    Zhang X; Ye S; Du X; Yuan J; Zhao C; Li C
    Biologicals; 2013 Nov; 41(6):364-7. PubMed ID: 23856276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Technology of immunoglobulin production. I. Technological aspects of purification].
    Volkov GL
    Ukr Biokhim Zh (1999); 2006; 78(3):88-98. PubMed ID: 17100315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.
    Wasserman RL
    Expert Rev Clin Immunol; 2014 Mar; 10(3):325-37. PubMed ID: 24527947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.
    Kaveri SV; Dietrich G; Hurez V; Kazatchkine MD
    Clin Exp Immunol; 1991 Nov; 86(2):192-8. PubMed ID: 1934588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use.
    Chérin P; Cabane J
    BioDrugs; 2010 Aug; 24(4):211-23. PubMed ID: 20623988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The viral safety of intravenous immune globulin.
    Yap PL
    Clin Exp Immunol; 1996 May; 104 Suppl 1():35-42. PubMed ID: 8625542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International collaborative study to evaluate a candidate reference preparation to define an appropriate specified limit of anti-D in intravenous immunoglobulin products.
    Thorpe SJ; Fox B; Heath A; Dolman C; Virata ML; Yu MW; Thorpe R
    Vox Sang; 2005 May; 88(4):278-87. PubMed ID: 15877651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-resolution physicochemical characterization of different intravenous immunoglobulin products.
    Washburn N; Meccariello R; Hu S; Hains M; Bhatnagar N; Sarvaiya H; Kapoor B; Schaeck J; Pino I; Manning A; Lansing JC; Bosques CJ
    PLoS One; 2017; 12(7):e0181251. PubMed ID: 28759653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.